Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
United European Gastroenterology Journal|June 9, 2018
'Missed' oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus patients: A large population-based studyMargreet van Putten, Brian T Johnston, Liam J Murray, et al.
The Journal of Pathology. Clinical Research|January 4, 2026
Prognostic significance of beta-adrenergic receptor expression in oesophageal adenocarcinomaTalita Oliveira, Swathi Sasi, James Trainor, et al.
British Journal of Cancer|July 2, 2021
Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based studyAshleigh C Hamilton, David W Donnelly, Maurice B Loughrey, et al.
Oncotarget|October 23, 2018
Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort studyStephen McCain, James Trainor, Damian T McManus, et al.
Molecular Cancer Therapeutics|June 6, 2012
Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cellsWendy L Allen, Richard C Turkington, Leanne Stevenson, et al.
Cancers|August 12, 2022
Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening ApproachesNiamh H McCabe, Leanne Stevenson, Enya Scanlon, et al.
Oncotarget|November 20, 2018
Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort studyÚna C McMenamin, James Trainor, Helen G Coleman, et al.
BMC Cancer|June 4, 2020
The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitationMatthew P Humphries, Stephanie G Craig, Rafal Kacprzyk, et al.
Scientific Reports|December 31, 2024
Inhibition of AKT enhances chemotherapy efficacy and synergistically interacts with targeting of the Inhibitor of apoptosis proteins in oesophageal adenocarcinomaLeanne Stevenson, Lauren Cairns, Xiaodun Li, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2019
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinomaAnne Thomas, Pradeep S Virdee, Martin Eatock, et al.
Pageof 4